Schwarcz Robert M, Ben Simon Guy J, Cook Todd, Goldberg Robert A
Jules Stein Eye Institute and Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Am J Ophthalmol. 2006 Feb;141(2):333-9. doi: 10.1016/j.ajo.2005.09.026.
To evaluate the outcome of sodium morrhuate 5% injections in patients with low flow vascular lesions, which consist of orbital lymphangiomas, and in one patient with intraosseous cavernous hemangioma.
Prospective, interventional consecutive case series.
Intralesional sodium morrhuate 5% was injected under direct visualization or under radiographic guidance to six patients with orbital lymphangiomas and one patient with intraosseous cavernous hemangioma. Comprehensive eye examination and follow-up imaging studies were performed. main outcome measures: Lesion size was evaluated by orbital imaging and clinical examination, visual acuity, exophthalmos, and posttreatment complications.
Seven patients (four female, three male; average age, 33 years) were included. Six patients were diagnosed with orbital lymphangioma, and one patient was diagnosed with intraosseous cavernous hemangioma. Patients received an average of 2.6+/-2 intralesional injections of sodium morrhuate, with a range of one to six injections and a mean volume of 0.9+/-0.8 ml (range, 0.2 to 2.1 ml). Lesions showed a decrease in size an average of 50% (33%) and ranged from minimal (10%) to near total resolution (85%). Visual acuity and intraocular pressure remained unchanged; exophthalmos decreased an average of 1.5+/-1.8 mm. Complications included one case of orbital hemorrhage that resolved spontaneously and transient keratopathy in all patients with anterior orbital lesions.
Intralesional sclerosing therapy with sodium morrhuate 5% is effective in tumor debulking in patients with orbital lymphangioma and is not associated with vision-threatening complications. It may be a better alternative to surgery for low flow orbital tumors, which includes lymphangioma.
评估5%鱼肝油酸钠注射治疗低流量血管性病变患者的疗效，这些病变包括眼眶淋巴管瘤，以及1例骨内海绵状血管瘤患者。
前瞻性、介入性连续病例系列研究。
在直视或影像学引导下，对6例眼眶淋巴管瘤患者和1例骨内海绵状血管瘤患者进行瘤内注射5%鱼肝油酸钠。进行全面的眼部检查和随访影像学检查。主要观察指标：通过眼眶成像和临床检查评估病变大小、视力、眼球突出度及治疗后并发症。
纳入7例患者（4例女性，3例男性；平均年龄33岁）。6例诊断为眼眶淋巴管瘤，1例诊断为骨内海绵状血管瘤。患者平均接受2.6±2次瘤内鱼肝油酸钠注射，注射次数范围为1至6次，平均注射量为0.9±0.8 ml（范围0.2至2.1 ml）。病变大小平均减小50%（33%），减小范围从最小（10%）至接近完全消退（85%）。视力和眼压保持不变；眼球突出度平均降低1.5±1.8 mm。并发症包括1例眼眶出血，自行消退，以及所有眼眶前部病变患者均出现短暂性角膜病变。
5%鱼肝油酸钠瘤内硬化治疗对眼眶淋巴管瘤患者的肿瘤减容有效，且不伴有威胁视力的并发症。对于包括淋巴管瘤在内的低流量眼眶肿瘤，它可能是手术的更好替代方法。
